T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT01078337
First received: February 26, 2010
Last updated: March 1, 2010
Last verified: February 2010

February 26, 2010
March 1, 2010
November 2002
October 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01078337 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
T-cell MRD Evaluation Using Flow Cytometric Analysis

To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

blood and bone marrow

Non-Probability Sample

children with newly diagnosed T-cell ALL

Leukemia, Lymphocytic, Acute
  • Procedure: bone marrow aspiration
  • Procedure: peripheral blood sampling
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
October 2007
October 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children with newly diagnosed T-cell ALL
Both
up to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01078337
SU-11022007-790, PEDSALL0001
Not Provided
Gary V Dahl, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Gary V Dahl Stanford University
Stanford University
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP